|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 186,700.00 KRW | +0.54% |
|
+2.25% | +3.56% |
| 12-11 | Celltrion USA, Inc. announced that it expects to receive $532.1 million in funding from Celltrion, Inc. | CI |
| 12-03 | Celltrion Announces U.S. FDA Approval of 300mg strength of OMLYCLO®? | CI |
Published on 10/24/2024
The Board of Directors of Celltrion, Inc. has authorized a buyback plan on October 25, 2024.
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Select your edition
All financial news and data tailored to specific country editions
